A new review advocates for building confidence in AI applications by implementing robust data governance frameworks, enhancing transparency, and involving stakeholders. The authors emphasize the importance of addressing ethical implications and ensuring equitable access to AI-driven innovations in clinical oncology.
NGR Oncology has created a new Sarcoma Subcommittee to improve outcomes for adults with cancer, focusing on building a robust program, collaborating with the Children's Oncology Group, and promoting sarcoma research. The subcommittee is led by Chair Dian Wang, MD, PhD, and Vice-Chairs William Tseng, MD, and Brian A Van Tine, MD, PhD.
At the 2025 Oncology Nursing Society Congress, Dana-Farber nurse scientists and clinicians presented key studies on hypersensitivity reaction simulation, bispecific antibody therapy, primary nursing, and non-pharmacologic interventions for anxiety and pain reduction. These research initiatives aim to enhance patient care, education, an...
The National Comprehensive Cancer Network (NCCN) has awarded four early-career oncologists with $150,000 in funding to tackle pressing challenges in cancer care. The recipients will support studies aiming to improve cancer outcomes through molecular residual disease-guided adjuvant therapy and electronic symptom monitoring.
The new Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging Center offers biology-guided radiation therapy, using up-to-the-minute signals to track and treat cancer cells in real time. The center is equipped with state-of-the-art technology and will be the first in Orange County to provide this treatment option.
Jeffrey E. Lee, M.D. has been appointed Chief Medical Executive at MD Anderson, succeeding Dr. Peter WT Pisters. With over 34 years of tenure, Lee will lead the institution's efforts in research, patient care, prevention, and education. He brings a strong track record of leadership and clinical expertise to the role.
The collaboration aims to enhance clinical trial efficiency, reducing data entry time by up to 37 seconds per CRF. This enables researchers to focus more on patient care, improving the overall experience.
The NRG Oncology GOG-0263 phase III clinical trial found that adding cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy did not improve outcomes and led to increased toxicity. Radiotherapy alone remains the standard of care for early-stage, intermediate-risk cervical cancer.
The F. W. Bert and Mae Dean Wheeler Nurse Leadership Academy at MD Anderson aims to cultivate oncology nurse leaders through coaching, mentoring, and continuous learning opportunities. The academy will focus on empowering nurses to reach their personal and professional goals, driving industry change and improving healthcare systems.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for anal cancer, providing guidance on treatment options and techniques. The guideline recommends a combination of radiation therapy and drug therapy as the standard of care, with intensity-modulated radiation therapy (IM...
Kimberly Stegmaier appointed as Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of Division of Hematology/Oncology at Boston Children's Hospital. She will focus on acute leukemias and pediatric solid tumors, pioneering genomic approaches to identify new therapies for childhood cancer.
Dr. Gordon was named a Fellow of the American Society of Clinical Oncology (FASCO) in recognition of his extraordinary dedication to improving cancer research and patient outcomes. He has led HonorHealth Research Institute's clinical trials programs and contributed significantly to developing new cancer treatments.
The ACC Advancing the Cardiovascular Care of the Oncology Patient conference will provide clinicians with tools to improve cardiovascular care of cancer patients. Key sessions will include discussions on pulmonary tumor thrombotic microangiopathy, AI and technology in cardio-oncology.
The Neuro-Oncology Translational Research Training Program aims to bridge laboratory discoveries and clinical applications in neuro-oncology, targeting glioblastoma and brain metastases. The program provides predoctoral and postdoctoral trainees with cutting-edge lab experience and mentorship across multiple disciplines.
A new study published in Neuro-Oncology found that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously thought. The study suggests that doctors may need to rethink current screening guidelines for detecting brain metastasis in patients without symptoms.
Jeremy L. Davis, MD, has been appointed as the new Surgical Oncology Lead for UMGCCC and Chief of the Division of Surgical Oncology in the Department of Surgery at UMSOM. Dr. Davis is a nationally recognized surgical oncologist with expertise in gastric cancer research.
The Fourth Transatlantic Exchange in Oncology Conference will focus on Radiopharmaceutical Therapy Meets Oncology, with key presentations on precision oncology and radioligand therapies. The meeting aims to facilitate the exchange of information and talents toward one goal: curing cancer.
NRG Oncology has established a new Theranostics Subcommittee to develop a more robust theranostics program within its portfolio. The subcommittee will serve as a resource for research investigators and collaborate with other organizations to enhance the effects of treatment on targeted cancer.
A Phase III clinical trial found that stereotactic body radiotherapy (SBRT) added to sorafenib improved progression-free survival and overall survival in patients with locally advanced hepatocellular carcinoma, particularly those with macrovascular invasion. The study also showed improvements in quality of life for these patients.
The European Society of Cardiology emphasizes the importance of including heart and cardiovascular health in cancer treatment plans. Recent studies estimate that approximately one-third of patients experience mild toxicities, while 3% develop moderate toxicity. The ESC is launching a new conference to address this growing epidemic.
Researchers analyzed data from 11,797 adults with advanced solid cancers and found no difference in mortality rates during the shortage period. Prescription rates for cisplatin and carboplatin fell less than three percent overall, with alternative therapies helping mitigate the crisis.
A team of UNC-Chapel Hill researchers will develop an oncology health learning system using AI-ready data to generate real-time identification of new cancer cases and support personalized treatments. The project aims to improve cancer diagnosis, care equity, and quality by creating accessible tools for health providers.
The ESMO Immuno-Oncology Congress 2024 will present key findings on new therapeutic opportunities and management of treatment-related toxicities. Leading experts will share their research advancements in the rapidly evolving field of immuno-oncology.
The Gustave Roussy Prize recognizes scientists whose work improves cancer treatment and patient outcomes. Established by Pierre Fabre Laboratories, the €200,000 award aims to push boundaries of oncology and offer personalized treatments.
The National Comprehensive Cancer Network (NCCN) is collaborating with leading cancer centers in China to improve cancer treatment and outcomes. NCCN Guidelines provide evidence-based recommendations for cancer treatment, prevention, and supportive care, guiding high-quality care globally.
Neuro-oncology experts developed guidelines to standardize AI use in brain cancer diagnosis and treatment. The recommendations aim to ensure reliable clinical trial results and protect patients.
Tiffany Richards, a seasoned oncology nurse supervisor, receives the prestigious award for her exceptional patient care and dedication to clinical excellence. She joins an elite group of nursing professionals who have made significant contributions to advancing cancer treatment.
The NRG Oncology trial found that atezolizumab given concurrently with chemoradiation did not improve overall survival for patients with limited-stage small cell lung cancer. However, the study suggests that LS-SCLC patients benefit from immunotherapy when given after completion of chemoradiation.
A randomized trial halted after patients in the control arm reached a record high two-year progression-free survival rate of 98%. Deintensified treatments involving lower radiation dose and immunotherapy did not perform as well as standard chemoradiation.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
Leading researchers from Penn Medicine will showcase clinical trial results and new data on FLASH radiation therapy. The institution is one of the world’s leading academic medical centers, with a proud history of groundbreaking discoveries and innovations.
The Cancer Cooperative Group System is being re-engineered to bring new money to correlative science research through public-private partnerships, aiming to remove barriers for researchers to access biological samples. This will facilitate the integration of innovative science into cancer clinical trials.
A new study from NRG Oncology found that whole-breast irradiation (WBI) was not statistically equivalent to accelerated partial-breast irradiation (APBI) in local tumor control. The QOL sub-study also showed that APBI may be preferred by some patients due to reduced fatigue and extended treatment time.
SourceNRG Oncology·JournalJNCI Journal of the National Cancer Institute·TypeRandomized controlled/clinical trial·DateSep 16, 2024
A new study published in Annals of Oncology found that long-course radiotherapy is safer and more effective than short-course radiotherapy for preserving organs in rectal cancer patients. The treatment was shown to prevent regrowth of the primary tumour, but had similar overall survival rates.
Researchers found that adding metastasis-directed radiation therapy to standard chemotherapy improved progression-free survival by 7.8 months in patients with oligometastatic pancreatic cancer. The approach also showed increased immune responses and longer survival times.
A year-long pilot program found that external mentorship increased confidence, furthered career development, and facilitated networking opportunities for trainees in classical hematology. The program paired hematology/oncology fellows with mentors outside their institutions to meet virtually each month.
A new AI protocol called DeepHRD enables accurate, instantaneous detection of cancer genomic biomarkers directly from tumor biopsy slides. This breakthrough technology saves weeks and thousands of dollars from clinical oncology treatment workflows, providing access and equity in cancer care for resource-constrained settings.
A new study found that two Medicaid policies can interact to increase oncology clinical trial enrollment among Black and Hispanic patients. Medicaid expansion under the ACA alone did not improve diversity, but states with pre-existing mandates requiring coverage of clinical trial costs saw a significant increase.
New article outlines considerations for clinical trial design to enhance OS collection and analysis. Key findings include the importance of prespecified statistical analyses of OS as a safety endpoint and robust assessments to support approval.
A recent study published in the Journal of Clinical Oncology found that combining different chemotherapy drugs improves testicular cancer's treatability and often curability, even after first-line treatment fails. The study showed a nearly 80% response rate and no significant drop-off in survival over 10 years.
A study by UC Irvine found that the ePRO tool improved symptoms management for Hispanic and Asian patients undergoing chemotherapy, reducing pain, nausea, and vomiting. The tool, which uses real-time analytics and personalized treatment plans, also increased patient satisfaction.
The study establishes criteria for identifying extranodal extension on imaging, allowing radiologists to make accurate calls and provide patients with less invasive treatments. This shift towards practice change has the potential to reduce side effects and improve outcomes for patients with HPV-associated head and neck cancers.
The article reviews recent advances in applying artificial intelligence to oncology, showcasing promising improvements in cancer care. The authors emphasize the need for interdisciplinary collaboration, rigorous validation, and ethical principles to harness AI's potential.
Researchers at MD Anderson Cancer Center found fewer side effects with intensity-modulated radiotherapy (IMRT), with similar survival outcomes compared to 3D-CRT. The study validated heart exposure as an important radiation planning objective, revealing better five-year overall and progression-free survival rates for IMRT.
St. Jude researchers found that early surveillance after genetic predisposition discovery detects new, treatable tumors in 70% of cases. This approach can avoid chemotherapy and radiation, improving outcomes for children with cancer.
The American Society for Radiation Oncology (ASTRO) has published an updated clinical guideline for treating patients with HPV-related oropharyngeal squamous cell carcinoma. The guideline emphasizes the importance of tailored radiation strategies to maximize patient survival while minimizing side effects. It provides recommendations fo...
The American Society for Radiation Oncology has released new guidelines for radiation therapy in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), recommending optimal dosing regimens to reduce acute and late effects. Concurrent chemotherapy with cisplatin is recommended for more advanced tumors or multiple lymph nodes.
The NRG-RTOG 0848 clinical study found that adding chemoradiation to adjuvant systemic therapy improves overall survival for node-negative pancreatic cancer patients, but not for those with node-positive disease. Disease-free survival was also improved in both groups.
A study published in Frontiers in Oncology reveals breast cancer incidence has surged in oil-rich Gulf countries, with unique clinical and pathological features. The disease is attributed to a combination of menstrual cycle, hereditary factors, weaning children earlier than expected, hormonal treatment, obesity, and use of contraceptives.
Researchers found disparities in LGBTQ+ patient experiences, including discomfort with disclosure and lack of partner respect. International medical graduates face unconscious bias, limited opportunities, and financial stress, affecting their engagement with healthcare systems.
Sharon Giordano and Richard Gorlick will be honored with Special Awards at the 2024 American Society of Clinical Oncology Annual Meeting for their dedication to improving cancer treatment and patient outcomes. Their research has made significant contributions to the field of oncology, with a focus on breast cancer and pediatric oncology.
The study found a 5.7% blood culture positive rate among eligible Hem-Onc patients, with 56% having an absolute neutrophil count greater than 500 µL at presentation. Gram-positive organisms were the most common isolates, highlighting the diversity of bloodstream infection causes in this patient population.
The updated clinical guideline recommends multiple dose-fractionation schemes to relieve pain and symptoms of bone and spine lesions. Advanced radiation techniques like intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) are now routine clinical care for many patients.
The American Society for Radiation Oncology's (ASTRO) 66th Annual Meeting will be held in Washington, D.C., featuring over 170 exhibitors showcasing state-of-the-art cancer care technologies. Registered attendees can access livestreams of scientific and educational sessions, both in-person and virtually.
Two new Review articles explore AI's application in early cancer detection, highlighting its potential to enhance diagnostic accuracy and improve treatment selection. The articles emphasize the need for a robust, multi-disciplinary approach to integrate AI into medicine.
The NCCN 2024 Annual Conference shared updates on improving cancer care worldwide, including plenary sessions on drug shortages and hereditary cancer risk. Key takeaways include the need for transparency around oncology supply chains and the importance of genetic testing to reduce cancer risk.
A Northwestern University study found ChatGPT's responses to radiation oncology patient questions were on par or exceeded professional society answers. The AI technology aims to empower patients before and after seeing physicians, while also reducing clinician burnout.
The DTEP model accurately predicts delayed treatment effects (DTE) in immuno-oncology trials, allowing for optimized trial designs. By tailoring trial lengths, the model enhances statistical power and accelerates immunotherapy development.
A new acceptable practice standard for hypofractionated post-prostatectomy radiotherapy has been established based on the NRG Oncology trial findings. The study showed that HYPORT was non-inferior to COPORT in terms of late GI or GU toxicity, with greater short-term GI toxicity associated with HYPORT but resolving at 6 months following...
Alex Jaeger, a Moffitt Cancer Center researcher, has received the Damon Runyon-Rachleff Innovation Award for his project on exploiting MHC-II antigen presentation in cancer. His goal is to develop advanced immunotherapeutic strategies by understanding how distinct patterns of antigen presentation trigger specific T-cell pathways.